SNCAIP and Parkinson disease: E2 treatment led to a statistically significant antagonism of IGF1R with the subunits ATP5A1, ATP5G1, and ATP5O of the ATP synthases H+ transporting complexes and reduced the synergistic coupling with the Parkinson's disease SNCAIP (synuclein alpha interacting protein; Figure S3A).